Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ibritumomab tiuxetan (Zevalin) (1 trial)
Aggression (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Trials (1 total)
Trial APIs (1 total)